Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

In this analysis, we examined the relationship between progression-free survival (PFS) and mutation status of 18 homologous recombination repair (HRR) genes in patients in the non-germline BRCA-mutated (non-gBRCAm) cohort of the ENGOT-OV16/NOVA trial (NCT01847274), which evaluated niraparib maintena...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirza, Mansoor Raza, Lindahl, Gabriel, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Rimel, Bobbie J., Herrstedt, Jørn, Oza, Amit M., Canzler, Ulrich, Berek, Jonathan S., González-Martín, Antonio, Follana, Phillipe, Lord, Rosemary, Azodi, Masoud, Estenson, Kasey, Wang, Zebin, Li, Yong, Gupta, Divya, Matulonis, Ursula, Feng, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035404/
https://www.ncbi.nlm.nih.gov/pubmed/36970052
http://dx.doi.org/10.1158/2767-9764.CRC-22-0240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035404/
https://www.ncbi.nlm.nih.gov/pubmed/36970052
http://dx.doi.org/10.1158/2767-9764.CRC-22-0240

Ejemplares similares